Madrigal Pharmaceuticals, Inc. (MDGL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Madrigal Pharmaceuticals, Inc. (MDGL) is down 11.9% since the beginning of the year. At $513 per share, MDGL is trading 16.6% below its 52-week high of $615. Investors who bought $1,000 worth of MDGL shares 5 years ago would now be looking at an investment worth $5,076.

Madrigal Pharmaceuticals, Inc. (MDGL) has returned -11.93% so far this year and 79.50% over the past 12 months. Looking at the last ten years, MDGL has achieved an annualized return of 47.15%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Feb 6, 2007, MDGL's average daily return is +0.17%, while the average monthly return is +3.72%. At this rate, an investment would double in approximately 1.6 years.

Historically, 47% of months were positive and 53% were negative. The best month was Dec 2022 with a return of +314.0%, while the worst month was Feb 2009 at -84.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, MDGL closed higher 48% of trading days. The best single day was Dec 19, 2022 with a return of +268.1%, while the worst single day was Feb 27, 2009 at -78.7%.

Madrigal Pharmaceuticals, Inc. has an annualized alpha of 39.07%, beta of 1.02, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since February 06, 2007.

• This stock participated in 126.28% of S&P 500 Index downside but only 98.84% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MDGL ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Madrigal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Madrigal Pharmaceuticals, Inc. was 98.40%, occurring on Feb 11, 2016. Recovery took 2396 trading sessions.

The current Madrigal Pharmaceuticals, Inc. drawdown is 14.92%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Madrigal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Madrigal Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.